Xeris Biopharma Holdings Inc. (XERS)
XERS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/0001867096-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XERS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001867096 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $291.8M |
| Net income | $554K |
| Operating income | $24.9M |
| Net margin | 0.2% |
| Operating margin | 8.5% |
| Revenue growth | +43.7% |
| Cash | $111.0M |
| Total assets | $383.5M |
| P/E (computed) | 5507.4× |
| P/S (computed) | 10.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $131.1M cash; operating cash flow $18.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 182,700,038 (2026-10-31); 165,924,289 a year earlier; 138,124,595 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Grand Rapids, Michigan, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $5.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $107.2M | $11.3M | $35.5M | $131.1M | $189.7M | $368.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $92.1M | -$31.1M | $8.3M | $121.7M | $252.6M | $335.4M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $83.1M | $2.2M | $9.9M | $111.8M | $221.2M | $314.9M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $85.8M | $11.1M | $20.0M | $111.0M | $220.3M | $291.8M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $74.4M | $621K | $18.4M | $91.6M | $219.5M | $266.1M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $71.5M | -$1.9M | $182K | $59.3M | $218.6M | $246.0M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $60.1M | -$9.2M | -$10.0M | $58.4M | $229.8M | $222.6M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $60.1M | -$5.1M | $2.0M | $71.6M | $232.1M | $203.1M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-03-06 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 346 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.6% |
| 1 month | +63.3% |
| 3 months | +100.0% |
| Year to date | +112.2% |
| 1 year | +129.5% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLX | Telix Pharmaceuticals Limited | $8.92 | -3.36% | $3.0B |
| LEGN | Legend Biotech Corporation | $15.99 | -8.63% | $3.1B |
| DYN | Dyne Therapeutics Inc. | $16.70 | -2.68% | $3.1B |
| BHC | Bausch Health Companies Inc. | $8.42 | +0.84% | $3.2B |
| IDYA | IDEAYA Biosciences Inc. | $30.36 | -4.62% | $2.9B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.67 | -0.43% | $3.2B |
| VCRE | Vicore Pharma Holding AB | $10.16 | -1.93% | $2.9B |
| VRDN | Viridian Therapeutics Inc. | $29.80 | -3.47% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier